ENTITY
Akeso

Akeso (9926 HK)

368
Analysis
Health Care • China
Akeso is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative antibody drugs. It develops treatments for major diseases such as cancer, autoimmune diseases, inflammation, and metabolic diseases, with key products including cadonilimab, ivonescimab, and penpulimab. The company was founded in 2012 and is headquartered in Zhongshan, Guangdong, China.
more
•07 Jun 2026 11:10

HSCEI June 2026 Index Rebalance: Pre-Implementation Update

HSCEI enters the implementation phase on 8 Jun 2026. We update stock pre-implementation performance and discuss implementation trades.

Logo
136 Views
Share
•07 Jun 2026 10:05

HK Connect Flows Weekly (Jun 5th): Smic, China Mobile, Akeso, Pop Mart Intl, CNOOC, Xiaomi, Lenovo

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Smic, China Mobile, Akeso, Pop Mart Intl, CNOOC, Xiaomi,...

Logo
149 Views
Share
bullish•Baidu
•02 Jun 2026 18:36

HSI, HSCEI, HSTECH, HSIII, HSBIO Index Rebalance: US$6.3bn of Flows Post Capping (June 2026)

The June rebalance of the HSI, HSCEI, HSTECH, HSIII, HSHKBIO indices will use 2 June closing prices for capping. The round-trip trade across the...

Logo
221 Views
Share
•01 Jun 2026 10:31

MS-China Index Earning Revision (May): Xinjiang Daqo, TENCENT, MEITUAN, TONGWEI, XIAOMI, PDD, NTES

We analyzed MS-China's consensus for May 2026 and highlighted changes of EPS in Xinjiang Daqo, TENCENT, MEITUAN, TONGWEI, XIAOMI, PDD, NTES.

Logo
143 Views
Share
bullish•Z.AI
•26 May 2026 05:30

Hang Seng Indexes: Changes Lead to US$6.6bn Trade; Plus Stock Connect & Global Index Inclusions

There are a number of constituent, float and capping changes for the Hang Seng family, leading to a US$6.6bn trade. Stock Connect additions, lock...

Logo
414 Views
Share
x